Nawaf Yassi Selected Research

Tenecteplase

1/2022	Safety and Efficacy of Tenecteplase in Older Patients With Large Vessel Occlusion: A Pooled Analysis of the EXTEND-IA TNK Trials.
1/2022	Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit-TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit.
1/2022	Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow).
1/2022	Reduced Severity of Tissue Injury Within the Infarct May Partially Mediate the Benefit of Reperfusion in Ischemic Stroke.
1/2022	Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
11/2021	Association between pre-treatment perfusion profile and cerebral edema after reperfusion therapies in ischemic stroke.
1/2021	Tenecteplase vs Alteplase Before Endovascular Therapy in Basilar Artery Occlusion.
12/2020	Cost-Effectiveness of Tenecteplase Before Thrombectomy for Ischemic Stroke.
1/2020	Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study.
1/2020	Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nawaf Yassi Research Topics

Disease

35	Stroke (Strokes) 01/2022 - 09/2013
27	Ischemic Stroke 01/2022 - 11/2013
7	Dementia (Dementias) 11/2022 - 01/2018
6	Cognitive Dysfunction 01/2022 - 01/2018
6	Brain Edema (Cerebral Edema) 01/2022 - 01/2019
5	Hematoma 03/2022 - 11/2013
5	Hemorrhage 03/2022 - 11/2013
5	Alzheimer Disease (Alzheimer's Disease) 02/2022 - 01/2018
5	Infarction (Infarctions) 01/2022 - 01/2016
4	Cerebral Hemorrhage 03/2022 - 06/2014
3	Edema (Dropsy) 01/2022 - 01/2019
3	Cerebral Infarction 01/2022 - 01/2018
3	Atrophy 01/2020 - 01/2016
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2020 - 01/2020
2	Thrombosis (Thrombus) 05/2019 - 01/2018
2	Body Weight (Weight, Body) 01/2018 - 03/2015
2	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2018 - 03/2015
1	Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease) 11/2022
1	Disease Progression 06/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2022
1	Hypercholesterolemia 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2022
1	COVID-19 12/2021
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2021
1	Wounds and Injuries (Trauma) 12/2020
1	Lewy Body Disease (Lewy Body Dementia) 11/2020
1	Parkinson Disease (Parkinson's Disease) 11/2020
1	Tauopathies 11/2020
1	Intracranial Thrombosis (Cerebral Thrombosis) 01/2020
1	Neurogenic Inflammation 01/2019
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2019
1	Neurologic Manifestations (Neurological Manifestations) 01/2019
1	Lacunar Stroke 07/2016
1	Traumatic Brain Injuries (Traumatic Brain Injury) 03/2016
1	Arteriovenous Malformations (Arteriovenous Malformation) 05/2014
1	Hereditary Hemorrhagic Telangiectasia 05/2014

Drug/Important Bio-Agent (IBA)

19	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022 - 09/2013
13	Tenecteplase FDA Link 01/2022 - 01/2018
8	Biomarkers (Surrogate Marker)IBA 11/2022 - 06/2014
8	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2018
5	Cytidine Triphosphate (CTP)IBA 01/2020 - 11/2013
4	Tranexamic Acid (AMCA)FDA Link 03/2022 - 06/2014
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2022 - 01/2022
2	Apolipoproteins E (ApoE)IBA 01/2022 - 01/2021
2	salicylhydroxamic acid (SHAM)IBA 01/2019 - 01/2019
2	N-acetylaspartate (N-acetyl aspartate)IBA 04/2016 - 01/2016
2	CreatineIBA 04/2016 - 01/2016
1	Biological ProductsIBA 06/2022
1	Amyloid beta-PeptidesIBA 02/2022
1	GadoliniumIBA 01/2022
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2022
1	C-Reactive ProteinIBA 12/2021
1	Glucose (Dextrose)FDA LinkGeneric 11/2021
1	ApolipoproteinsIBA 01/2021
1	tau Proteins (tau Protein)IBA 11/2020
1	Substance PIBA 01/2019
1	TachykininsIBA 01/2019
1	Aligeron (AS 2)IBA 01/2019
1	Metformin (Glucophage)FDA LinkGeneric 12/2016
1	Warfarin (Coumadin)FDA LinkGeneric 12/2016
1	Glutamic Acid (Glutamate)FDA Link 04/2016
1	Inositol (Myoinositol)IBA 01/2016
1	2,6-dinitrotoluene (DNT)IBA 09/2013

Therapy/Procedure

22	Therapeutics 01/2022 - 06/2014
16	Thrombectomy 01/2022 - 03/2015
3	Catheters 01/2020 - 05/2014
2	Thrombolytic Therapy 12/2021 - 12/2020
2	Contraindications 01/2020 - 01/2018
2	Stents 01/2019 - 03/2015
1	Drug Therapy (Chemotherapy) 06/2022
1	Punctures 01/2022
1	Neurosurgical Procedures 01/2022
1	Subacute Care 12/2020
1	Length of Stay 12/2020
1	Patient Readmission 12/2020
1	Time-to-Treatment 05/2019
1	Decompressive Craniectomy 01/2019
1	Intravenous Infusions 01/2018
1	Craniotomy 03/2016
1	Aftercare (After-Treatment) 12/2014
1	Stretchers 09/2013